Early results evaluating the efficacy and toxicity of adriamycin, vincristine and etoposide Ave in the management of childhood hodgkin's disease
Assiut Medical Journal. 1998; 22 (1): 9-18
em Inglês
| IMEMR
| ID: emr-47558
ABSTRACT
This study aimed to evaluate efficacy and toxicity of adriamycin, vincristine and etoposide in the management of childhood Hodgkin's disease as a salvage and first line therapy as well as limiting the use of involved field radiotherapy to partial responders to avoid unnecessary complications of radiotherapy children. Thirty-six patients with Hodgkin's disease were included in this study, twenty- four had no previous treatment and twelve were previously treated with either C-MOPP or Chl-VPP [five of them had refractory disease and the remaining seven attained a complete remission but relapsed later]. All patients were treated with adriamycin 30 mg/m2, vincristine 1.4 mg/m2 and etoposide 100 mg/m2 D1 and D15 repeated every 28 days for six cycles. Partial responders [PR] were subjected to a field radiation treatment after three cycles of chemotherapy [20 Gy/ten treatments/two weeks]. At the end of the six cycles of chemotherapy, all patients were in a complete remission [CR]. All the previously untreated patients were in a complete remission after a median follow up of 15.5 months. The relapse free survival in previously treated patients was 58.3% after a median follow up of 14 months. The relapse free survival for the whole group was 86.7% after a median follow up of 15 months
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Vincristina
/
Doxorrubicina
/
Etoposídeo
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Assiut Med. J.
Ano de publicação:
1998
Similares
MEDLINE
...
LILACS
LIS